Purdue Opioid Fund: Victims Face Hurdles for Compensation

Compensation Hurdles for Opioid Victims

Purdue Pharma’s bankruptcy settlement, which allocates approximately $865 million for individuals harmed by the opioid crisis, is proving inaccessible for many victims. A stringent documentation requirement is causing a large number of claims to be rejected, leaving thousands without expected compensation.

The Documentation Challenge

The settlement requires claimants to provide concrete proof that they or their relatives were prescribed opioids manufactured specifically by Purdue, not a generic competitor. This rule was enforced years after the initial claims deadline, by which time many necessary medical and pharmacy records were no longer available or had been legally destroyed. As a result, over 40% of the nearly 140,000 claims have already been dismissed.

Financial and Legal Ramifications

The issue highlights the difficulty of distributing settlement funds directly to individuals in complex corporate bankruptcies. While the $57 billion in total opioid settlements is largely directed to governments, Purdue's individual fund was a key component for victim justice. The high rate of claim denials means the final payout per eligible person might increase, but it also underscores a procedural failure that prevents many victims from receiving financial relief.

Summary

The process has created a significant barrier for the very people the fund was intended to help. With tens of thousands of claims already expunged, the final distribution will likely fall short of compensating all individuals who suffered from the opioid crisis fueled by Purdue's marketing practices.

FAQ

Q: Why are Purdue opioid victims' claims being rejected?
A: Claims are being rejected primarily because victims cannot produce old records proving they used Purdue-manufactured OxyContin, not a generic version.

Q: How much is the Purdue settlement fund for individuals?
A: Approximately $865 million is designated for direct compensation to individuals harmed by Purdue's opioids.

Source: Investing.com